GE Vernova Q2 Revenue Tops Estimates as Earnings Miss, Shares Slide Despite Higher 2026 Outlook 
European Stocks Slip as Earnings, UK Inflation and ECB Decision Keep Investors on Edge 
US Dollar Pauses Rally as Middle East Tensions Support Safe-Haven Demand 
Japan Yen Slides Past 163 as Middle East Tensions Lift US Dollar, Oil Prices 
Nasdaq Drops as AI Earnings, Oil Surge and Middle East Tensions Weigh on Wall Street 
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay 
India FMCG Q1 Earnings Preview: Higher Input Costs Likely to Weigh on Profit Margins 
Samsung Cuts U.S. Consumer Electronics Jobs as Headquarters Moves to Texas 
Judge Approves Anthropic’s $1.5 Billion AI Copyright Settlement With Authors 
OpenAI Australia Data Center Switches Cooling Strategy After Recycled Water Plan Fails 
KPMG Australia Appoints John Sams as CEO Following Audit Leak Scandal 
Asian Stocks Rise as Oil Retreats on Iran Ceasefire Hopes Ahead of Key AI Earnings 
Super Micro Computer Stock Jumps 20% After Record AI Orders and Margin Surge 
Gold Price Climbs Above $4,130 as Middle East Tensions Boost Safe-Haven Demand 
South Korea Q2 GDP Beats Forecasts as AI Chip Exports Drive Growth 
Lotte Corporation recently formed Lotte Biologics as its newest business unit to venture further into the bio business sector. As the new division starts to operate independently, the company assigned an executive to lead the new team.
According to The Korea Herald, Lotte chose a former Samsung Biologics executive, Lee Won Jik, to be Lotte Biologics’ chief executive officer. He was only given the role of CEO now, but he actually Lotte Corporation in August of last year. Prior to his move, Lee worked as the head of Samsung Biologics’ drug business unit.
Lotte Holdings announced last week that it had completed the registration of Lotte Biologics with a starting capital of KRW1 billion or around $790,000. Lotte Biologics is now in charge of the company’s new bio business, and key executives were already appointed as well. An official at Lotte Holdings said that its bio unit and its new CEO will be formally introduced at the Bio International Convention that will start on Monday, June 13, in San Diego, California.
It was last month when the Lotte Group revealed its plans to inject KRW2.5 trillion to expand its bio ventures over the next 10 years. Its biggest goal for this new investment is to become one of the world’s top 10 largest CDMOs or contract development and manufacturing organizations by the year 2030.
In any case, the company’s entrance into the bio-industry started with Lotte’s acquisition of Bristol Myers Squibb’s production plant in East Syracuse, New York. The company purchased it for $160 million, and this will be where Lotte is producing drugs for its CMO contracts.
Meanwhile, Lee Won Jik started working at Lotte Holdings last year as the company’s vice president of its new growth team and head of the ESG Management Innovation Office. He has more than two decades of experience in the global biologics and the pharmaceuticals business because aside from being a former executive at Samsung Biologics, he also worked at Bristol Myers Squibb and the U.S. Department of Health and Human Services.
As per the report, Lee Won Jik was not the only executive to be given a new role as Lotte also appointed Ha Jong Su, the company’s VP of global logistics SCM business unit, as the new inside director while Lee Hong Gi, Lotte’s healthcare unit chief, becomes the non-executive director.
